Interplay of Anti-Viral Vaccines with Biologic Agents and Immunomodulators in Individuals with Autoimmune and Autoinflammatory Diseases

Immunol Invest. 2021 Oct;50(7):833-856. doi: 10.1080/08820139.2021.1900863. Epub 2021 May 3.

Abstract

Vaccines are an essential part of a preventative healthcare strategy. However, response to vaccines may be less predictable in immunocompromised people. While outcomes for individuals with autoimmune and autoinflammatory diseases have dramatically improved with treatment using immunomodulating and biologic agents, infections have caused significant morbidity in these people today often more than due to their underlying diseases. Immune-based biologic therapies contribute to these infectious complications. This review addresses anti-viral vaccines, their effectiveness and safety in patients treated with approved biologic agents and immune targeted therapy with a focus on vaccines against influenza, human papillomavirus, hepatitis B virus and varicella zoster virus. Preliminary information regarding SARS-CoV-2 anti-viral vaccines is addressed. Additionally, we present recommendations regarding the safe use of vaccines in immunocompromised individuals with the goal to enhance awareness of the safety and efficacy of these anti-viral vaccines in these high-risk populations.

Keywords: Autoimmune diseases; anti-viral vaccines; biologic therapy; immunomodulating therapy.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / immunology*
  • Biological Factors / immunology*
  • Hereditary Autoinflammatory Diseases / immunology*
  • Hereditary Autoinflammatory Diseases / virology
  • Humans
  • Immunologic Factors / immunology*
  • Inflammation / immunology*
  • Inflammation / virology
  • Virus Diseases / immunology*
  • Virus Diseases / virology
  • Viruses / immunology*

Substances

  • Antiviral Agents
  • Biological Factors
  • Immunologic Factors